RCS - Oxford Biomedica PLC - Oxford Biomedica rebrands as OXB

Oxford BioMedicaAnnouncement

18/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240918:nRSR5961Ea&default-theme=true

RNS Number : 5961E  Oxford Biomedica PLC  18 September 2024

 

Press release

 

 

Oxford Biomedica rebrands as OXB reinforcing transformation into leading
global cell and gene therapy CDMO

Oxford, UK - 18 September 2024: OXB (LSE:OXB), a quality and innovation-led
cell and gene therapy CDMO, today announces the launch of its new corporate
brand.

Oxford Biomedica is rebranding as OXB, unveiling a more modern and
recognisable visual identity that reinforces its transformation into a global
pure-play cell and gene therapy CDMO. The new identity reflects OXB's unique
combination of technical excellence, innovation and unwavering commitment to
deliver consistent high quality at every stage of viral vector development and
manufacturing. The new branding represents the agile execution and creativity
that enable OXB to deliver on clients' goals, while also conveying
accountability, professionalism and teamwork - core values that underpin OXB's
mission.

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "The launch of
our new brand identity reinforces OXB's significant transformation into a
leading pure-play cell and gene therapy CDMO. This rebranding is more than
just a new look - it reflects the global nature of our operations and our deep
commitment to the success of our clients' drug development programmes. As OXB,
with our new capabilities and global footprint, we are ideally positioned to
communicate our end-to-end services to current and potential clients, and to
interact with them from early-stage development through to commercial
manufacturing."

 

-Ends-

 

Enquiries:

 

OXB:

Sebastien Ribault, Chief Commercial Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com

ICR Consilium:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. OXB's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector
manufacturing, including a 4th generation lentiviral vector system (the
Tetravecta(TM) system), dual plasmid system for AAV production, suspension and
perfusion process using process enhancers and stable producer and packaging
cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/)  and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKOBBKBKBKCD